Gilead Gets Positive EU Opinion On Proprietary HCV Combo Pill Harvoni
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe’s top scientific advisory panel has cleared for approval Gilead’s new hepatitis C antiviral combination of sofosbuvir plus ledipasvir, as well as Almirall’s new inhaled combo of aclidinium and formoterol and AstraZeneca’s new constipation therapy naloxegol.